Olinvacimab Biosimilar – Anti-KDR, VEGFR2 mAb – Research Grade

Description of Olinvacimab Biosimilar - Anti-KDR, VEGFR2 mAb - Research Grade

Olinvacimab Biosimilar: A Novel Anti-KDR, VEGFR2 Monoclonal Antibody for Research Use Olinvacimab Biosimilar is a newly developed monoclonal antibody (mAb) targeting the vascular endothelial growth factor receptor 2 (VEGFR2) and its ligand, the kinase insert domain receptor (KDR). This biosimilar is a highly specific and potent therapeutic agent that has shown promising results in preclinical studies. In this article, we will explore the structure, activity, and potential applications of Olinvacimab Biosimilar as a research-grade antibody.

Structure of Olinvacimab Biosimilar

Olinvacimab Biosimilar is a recombinant, humanized IgG1 monoclonal antibody. It is produced using advanced genetic engineering techniques, where the variable regions of the antibody are derived from the original Olinvacimab, while the constant regions are from human IgG1. This process ensures that the biosimilar has a high affinity and specificity for its target, while also minimizing the risk of immunogenicity.

The antibody has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains, each with a unique variable region that recognizes the KDR/VEGFR2 complex. The binding site of Olinvacimab Biosimilar is located on the extracellular domain of VEGFR2, which is essential for its activity.

Mechanism of Action

Olinvacimab Biosimilar exerts its therapeutic effect by inhibiting the interaction between VEGFR2 and its ligand, VEGF. VEGF is a key regulator of angiogenesis, the process of forming new blood vessels, which is essential for the growth and metastasis of solid tumors. By binding to VEGFR2, Olinvacimab Biosimilar blocks the downstream signaling pathways that promote angiogenesis, thereby inhibiting tumor growth and metastasis.

Moreover, VEGFR2 is also involved in the maintenance of the endothelial barrier and the recruitment of immune cells to the tumor microenvironment. By targeting VEGFR2, Olinvacimab Biosimilar can also modulate the immune response against tumors, making it a potential immunomodulatory agent.

Potential Applications of Olinvacimab Biosimilar

Olinvacimab Biosimilar has shown promising results in preclinical studies, demonstrating its potential as a research tool for studying angiogenesis and tumor biology. Some of the potential applications of this biosimilar include:

1. Anti-Tumor Activity As mentioned earlier, Olinvacimab Biosimilar has the ability to inhibit tumor growth and metastasis by targeting VEGFR2. It has shown efficacy in various preclinical tumor models, including breast, lung, and colon cancer. This makes it a potential candidate for further development as an anti- cancer therapy.

2. Angiogenesis Inhibition Olinvacimab Biosimilar can also be used to study the role of VEGFR2 in angiogenesis. By blocking the VEGF-VEGFR2 signaling pathway, this biosimilar can help researchers understand the mechanisms underlying angiogenesis and identify potential targets for anti-angiogenic therapies.

3. Immunomodulation VEGFR2 is also involved in the recruitment and function of immune cells in the tumor microenvironment. Olinvacimab Biosimilar can be used to study the role of VEGFR2 in immune cell function and potentially identify new targets for immunotherapy.

4. Biomarker Development Olinvacimab Biosimilar can be used to identify potential biomarkers for predicting response to anti-angiogenic therapies. By studying the expression levels of VEGFR2 and other related proteins, researchers can identify patients who are more likely

Olinvacimab Biosimilar - Anti-KDR, VEGFR2 mAb binds to Human VEGFR2 Recombinant Protein in indirect ELISA Assay

Immobilized Human VEGFR2 Recombinant Protein (cat. No.PX-P3059) at 0.5µg/mL (100µL/well) can bind to Olinvacimab Biosimilar - Anti-KDR, VEGFR2 mAb (cat. No.PX-TA1520) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450